Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 neoadjuvant FL-101 in resectable non-small cell lung cancer
NL-OMON50938Phase 2Withdrawn
- Sponsor
- Flame Biosciences
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of abdakibart in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Flame Biosciences. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Incidence of immune-related toxicities and 2 more. Planned start Jul 2021; status: withdrawn.
02
Drugs
abdakibart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50938.